Short Interest in Abeona Therapeutics Inc (NASDAQ:ABEO) Decreases By 6.8%

Abeona Therapeutics Inc (NASDAQ:ABEO) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 2,480,000 shares, a drop of 6.8% from the January 15th total of 2,660,000 shares. Approximately 6.5% of the company’s stock are short sold. Based on an average trading volume of 273,400 shares, the days-to-cover ratio is currently 9.1 days.

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently bought and sold shares of the business. Western Standard LLC increased its holdings in Abeona Therapeutics by 22.8% in the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after buying an additional 386,321 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics in the 4th quarter worth about $67,000. Twinbeech Capital LP purchased a new position in Abeona Therapeutics in the fourth quarter worth about $58,000. OMERS ADMINISTRATION Corp purchased a new position in Abeona Therapeutics in the fourth quarter worth about $362,000. Finally, Balyasny Asset Management L.P. purchased a new position in Abeona Therapeutics in the fourth quarter worth about $190,000. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $5.85 on Wednesday. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01. The stock has a 50-day moving average of $5.66 and a 200 day moving average of $5.80. The company has a market capitalization of $254.30 million, a price-to-earnings ratio of -2.17 and a beta of 1.43. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ABEO shares. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 14th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.